Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects

Trial Profile

Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2015

At a glance

  • Drugs Acetylcysteine (Primary) ; Disufenton (Primary) ; Disufenton/acetylcysteine (Primary)
  • Indications Hearing loss; Noise-induced hearing loss; Sensorineural hearing loss
  • Focus Adverse reactions
  • Sponsors Otologic Pharmaceutics
  • Most Recent Events

    • 30 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Dec 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 30 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top